ENXTAM:PHARMBiotechs
Why Pharming Group (ENXTAM:PHARM) Is Up 22.9% After Raising Guidance and Leniolisib’s FDA Progress
On November 6, 2025, Pharming Group N.V. reported strong quarterly earnings with nine-month sales of US$269.6 million, up from US$204.53 million the previous year, and raised its full-year 2025 revenue guidance to between US$365 million and US$375 million.
A key development was the company's announcement that the FDA granted priority review for leniolisib's potential pediatric label expansion, signaling further growth opportunities for its rare disease portfolio.
With robust revenue momentum...